Several studies demonstrated that CD204+TAMs promote tumor development and correlate with worse prognoses in prostate cancer, lung cancer, colorectal cancer, cervical cancer, breast cancers and oral squamous cell carcinoma patients (24, 26, 27, 74–76). This evidence concerns the gene MSR1 and colorectal cancer.